Brenipatide is an experimental medication being tested as an additional (adjunctive) treatment for adults with major depressive disorder. In the study, it is given as a small amount of liquid that is injected under the skin (subcutaneous injection). The goal of adding Brenipatide to participants’ regular antidepressant medicines is to see if it can help keep their depression from returning for a longer time compared with a placebo.

Major Depressive Disorder – Major Depressive Disorder is a mental health condition marked by persistent low mood, loss of interest, and changes in sleep, appetite, and energy lasting at least two weeks. It can begin at any age, often emerging in adolescence or early adulthood. Without improvement, symptoms may intensify, making daily tasks, work, and relationships increasingly difficult. The illness often follows a pattern of episodes that can improve and then return. Over time, episodes may become more frequent or last longer, and some individuals experience chronic symptoms that persist for months or years. Periods of partial or full remission may alternate with new episodes.